Sunesis Pharmaceuticals, Inc. (SNSS) Sets New 52-Week Low at $2.11
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $2.11 and last traded at $2.11, with a volume of 82,222 shares. The stock had previously closed at $2.19.
Several research firms have issued reports on SNSS. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Tuesday, May 2nd. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, May 11th.
The company’s market cap is $49.38 million. The firm’s 50 day moving average price is $2.46 and its 200 day moving average price is $3.29.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.35. During the same quarter in the prior year, the business posted ($0.12) EPS. On average, equities research analysts predict that Sunesis Pharmaceuticals, Inc. will post ($1.61) EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in SNSS. Balyasny Asset Management LLC acquired a new stake in Sunesis Pharmaceuticals during the second quarter valued at $5,400,000. Virtu KCG Holdings LLC acquired a new stake in Sunesis Pharmaceuticals during the second quarter valued at $208,000. Vanguard Group Inc. raised its position in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. Wells Fargo & Company MN raised its position in Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its position in Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares in the last quarter. Hedge funds and other institutional investors own 49.86% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.